Evidence map›Paper›PMID 25392525›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2014

CD4+ T cell epitopes of FliC conserved between strains of Burkholderia: implications for vaccines against melioidosis and cepacia complex in cystic fibrosis.

Julie A Musson, Catherine J Reynolds, Darawan Rinchai, Arnone Nithichanon, Prasong Khaenam, Emmanuel Favry, Natasha Spink, Karen K Y Chu, Anthony De Soyza, Gregory J Bancroft and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Antibodies toMicroorganisms · 2026
    Article
  2. Article
  3. Vaccines · 2024
    Review
  4. Article
  5. Current Advances inCells · 2020
    Review
  6. Article
  7. Characterization of theVaccines · 2020
    Article
  8. Review
  9. Article
  10. Article
  11. Immune Control ofFrontiers in immunology · 2018
    Article
  12. Article
  13. Vaccines for the Prevention of Melioidosis and Glanders.Current tropical medicine reports · 2017
    Article
  14. Article
  15. Review
  16. Vaccine strategies against cystic fibrosis pathogens.Human vaccines & immunotherapeutics · 2016
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Julie A MussonInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, Tyne and Wear NE2 4HH, United Kingdom;
Catherine J ReynoldsSection of Infectious Diseases and Immunity, Department of Medicine, Imperial College, London W12 0NN, United Kingdom;
Darawan RinchaiCentre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand;
Arnone NithichanonCentre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand;
Prasong KhaenamCentre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand;
Emmanuel FavryCommiseriat à l'Energie Atomique, Insititut de Biologie et de Technologies de Saclay, Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), 91191 Gif Sur Yvette, France; and.
Natasha SpinkDepartment of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom.
Karen K Y ChuSection of Infectious Diseases and Immunity, Department of Medicine, Imperial College, London W12 0NN, United Kingdom;
Anthony De SoyzaInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, Tyne and Wear NE2 4HH, United Kingdom;
Gregory J BancroftDepartment of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom.
Ganjana LertmemongkolchaiCentre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand;
Bernard MaillereCommiseriat à l'Energie Atomique, Insititut de Biologie et de Technologies de Saclay, Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), 91191 Gif Sur Yvette, France; and.
Rosemary J BoytonSection of Infectious Diseases and Immunity, Department of Medicine, Imperial College, London W12 0NN, United Kingdom;
Daniel M AltmannSection of Infectious Diseases and Immunity, Department of Medicine, Imperial College, London W12 0NN, United Kingdom;
John H RobinsonInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, Tyne and Wear NE2 4HH, United Kingdom; john.robinson@ncl.ac.uk.
Imperial College London · GBKhon Kaen University · THNewcastle University · GBCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRInstitut de Biologie et Technologies · FRLondon School of Hygiene & Tropical Medicine · GBUniversity of London · GB

Funding

NIAID NIH HHS HHSN272200900046CPHS HHS HHSN272200900046C
6 · The paper itself

Abstract

Burkholderia pseudomallei is the causative agent of melioidosis characterized by pneumonia and fatal septicemia and prevalent in Southeast Asia. Related Burkholderia species are strong risk factors of mortality in cystic fibrosis (CF). The B. pseudomallei flagellar protein FliC is strongly seroreactive and vaccination protects challenged mice. We assessed B. pseudomallei FliC peptide binding affinity to multiple HLA class II alleles and then assessed CD4 T cell immunity in HLA class II transgenic mice and in seropositive individuals in Thailand. T cell hybridomas were generated to investigate cross-reactivity between B. pseudomallei and the related Burkholderia species associated with Cepacia Complex CF. B. pseudomallei FliC contained several peptide sequences with ability to bind multiple HLA class II alleles. Several peptides were shown to encompass strong CD4 T cell epitopes in B. pseudomallei-exposed individuals and in HLA transgenic mice. In particular, the p38 epitope is robustly recognized by CD4 T cells of seropositive donors across diverse HLA haplotypes. T cell hybridomas against an immunogenic B. pseudomallei FliC epitope also cross-reacted with orthologous FliC sequences from Burkholderia multivorans and Burkholderia cenocepacia, important pathogens in CF. Epitopes within FliC were accessible for processing and presentation from live or heat-killed bacteria, demonstrating that flagellin enters the HLA class II Ag presentation pathway during infection of macrophages with B. cenocepacia. Collectively, the data support the possibility of incorporating FliC T cell epitopes into vaccination programs targeting both at-risk individuals in B. pseudomallei endemic regions as well as CF patients.

Indexed as

AllelesAnimalsBacterial ProteinsBacterial VaccinesBurkholderiaBurkholderia InfectionsBurkholderia pseudomalleiCD4-Positive T-LymphocytesCross ReactionsCystic FibrosisEpitopes, T-LymphocyteHistocompatibility Antigens Class IIHLA-DR AntigensHumansImmunizationInterferon-gammaBacterial ProteinsBacterial VaccinesEpitopes, T-LymphocyteHistocompatibility Antigens Class IIHLA-DR AntigensInterferon-gammaPeptides

Identifiers

PMID25392525
PMCPMC4258416
OpenAlexW2158337773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.